Ex-Olympian Shawn Johnson East Shares Son’s Harrowing RSV Experience
Olympic gold medalist gymnast Shawn Johnson East had respiratory syncytial virus-related experiences with all 3 of her ...
FierceBiotech6d
With trial win, Merck's RSV antibody clesrovimab looks poised to take on Sanofi and AZ's Beyfortus
Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.
pharmaphorum5d
MSD preparing to take on Beyfortus with RSV antibody
In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...
STAT5d
Potential competition for RSV prophylactic Beyfortus
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
Ottawa10h
Ottawa Public Health recommends that high-risk residents protect themselves against RSV
Abrysvo® and Arexvy® are Health Canada-approved vaccines for preventing RSV-related lower respiratory tract disease in individuals 60 years of age and older, currently available for high-risk older ...
BioWorld5d
Merck’s clesrovimab tortoise to Beyfortus in RSV race?
Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...
MarketWatch10h
Sanofi Expected to Report Higher Sales; Capital Allocation in Focus -- Earnings Preview
Sanofi is likely to implement a buyback, Jefferies analysts said a note. -- Key Drugs: The uptake of Sanofi's respiratory syncytial virus treatment Beyfortus will be watched, UBS analysts said. Also ...
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...